Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The company's leadership in the GLP-1 drug market and its promising pipeline position it well for future growth, particularly in the expanding obesity treatment sector. However, increasing competition ...

BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related conditions that we can expect in the near future? VG: India is an important market for Lilly. We are committed to ...

However, the spotlight is on Amgen's obesity drug candidate ... idiopathic pulmonary fibrosis (IPF) These pipeline assets represent potential future growth drivers for the company, diversifying ...

Amgen's future outlook is largely tied to the success of its pipeline, particularly MariTide ... MariTide could become a preferred treatment option, potentially capturing a significant share of the ...

BOSTON and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

It also plans to evaluate once-monthly dosing of VK2735 SC in a future clinical ... VKTX’s Non-Obesity Pipeline Shows Potential Apart from VK2735, Viking is also developing drugs targeting ...